So far, the FDA has approved two CSF-1R inhibitors for patients with tenosynovial giant cell tumors, a tumor type characterized by chromosomal translocations of the CSF-1 gene, leading to aberrant CSF-1 expression [55–57]. This evidence concerns the gene CSF1 and neoplasm.